If M&A continues at this pace you want to be long Biotech into next year, says Mizuho's Jared Holz

Here's a comprehensive summary of the provided YouTube video transcript:

Key Concepts

• Patent Expirations: The looming loss of patent protection for major drugs, leading to revenue cliffs for pharmaceutical companies.
• Pipeline Replenishment: The strategic need for pharmaceutical companies to acquire new drugs or companies to fill the void left by expiring patents.
• "String of Pearls" Strategy: A method of acquiring multiple smaller assets or companies to build a future pipeline, as opposed to one large acquisition.
• Mergers & Acquisitions (M&A) Activity: The increased pace and volume of deals within the pharmaceutical and biotech sectors driven by patent cliff concerns.
• Valuation Multiples: The ratio of a company's market value to its revenue or earnings, used to assess whether a deal is overpaying.
• Biotech as an Investment: The current attractiveness of the biotech sector for investors due to M&A activity, despite broader healthcare sector risks.

Merck's Acquisition of Verona Pharma and Strategic Implications

The discussion centers on Merck's acquisition of Verona Pharma, a deal valued at approximately $4 billion. This acquisition is significant because Verona's lead drug, ensifentrine, is expected to face patent expiry around 2030-2031. The transcript highlights that this drug accounted for nearly half of Merck's projected revenues in 2024, underscoring the urgency for Merck to secure its future pipeline.

Merck's Valuation and Strategy:

• No Overpayment: The healthcare strategist, Jared, suggests Merck likely did not overpay for Verona Pharma. He bases this on the reported presence of multiple bidders, indicating a competitive acquisition process.
• Valuation Range: The deal's valuation is estimated to be in the 4 to 5 times revenue range, which is considered "pretty practical" and in line with recent industry transactions.
• "String of Pearls" Approach: Merck is employing a "string of pearls" strategy, which involves a series of smaller acquisitions (including Acceleron and Sadara, in addition to Verona) to supplement the future revenue gap left by Keytruda's impending patent expiry. This contrasts with a single, large acquisition.
• Addressing Keytruda's Patent Cliff: The primary driver for these acquisitions is the anticipated significant impact of Keytruda's patent expiry in the latter half of the decade.

Broader Industry Trends and M&A Fever

The Merck-Verona deal is presented as symptomatic of a larger trend of increased M&A activity across the pharmaceutical and biotech sectors.

Urgency and Scramble for Assets:

• Dire Situation for Big Pharma: Many large pharmaceutical companies are facing a "dire situation" due to patent expirations and are actively seeking to replenish their pipelines.
• Peer Companies: Companies like Bristol Myers Squibb, Sanofi, and Amgen are also identified as being in similar positions and are expected to become more acquisitive.
• Busy Year for Deals: 2026 is anticipated to be one of the busiest years on record for M&A in terms of the number of deals, though not necessarily the total dollar value spent.
• Biotech as a Hotbed: The biotech space, in particular, has been "on fire" with deal after deal since the summer, driven by the need for assets. Examples cited include transactions involving Matsura (with multiple bidders), Novo, Pfizer, Avadel (bid up by Lundbeck), and the Verona Pharma deal.

Investment Landscape and Sector Outlook

The heightened M&A activity has shifted the investment landscape for the healthcare sector.

Investability of Healthcare:

• Biotech as the Preferred Play: Jared expresses that only the biotech sector has been attractive for investment since the summer.
• Risks in Broader Healthcare: The rest of the healthcare sector is still perceived as being "encumbered with a lot of risks" and has historically underperformed the market.
• Strategy for Investors: For investors looking to capitalize on this trend, the strategy is to focus on small and mid-cap biotech companies, as they are the most likely targets for M&A.
• Sector Complexity: The healthcare sector is complex, encompassing multiple industry groups (managed care, medical devices, pharmaceuticals), making it challenging to analyze and invest in holistically.

Key Arguments and Perspectives

• Argument: Big pharma companies are under significant pressure due to patent expirations and are actively pursuing M&A to secure future revenue streams.
  • Evidence: Merck's acquisition of Verona Pharma, the "string of pearls" strategy, and the identification of peer companies like Bristol Myers Squibb, Sanofi, and Amgen as also being acquisitive.
• Argument: The current M&A environment in biotech is driven by a genuine need for assets rather than just speculative activity.
  • Evidence: The consistent deal flow since the summer and the mention of multiple bidders for various companies.
• Argument: While the broader healthcare sector faces risks, biotech presents a compelling investment opportunity due to M&A potential.
  • Evidence: The strategist's explicit preference for biotech and the acknowledgment of ongoing risks in other healthcare sub-sectors.

Notable Quotes

• "The cancer drug accounted for nearly half of Merck's revenues in 2024." (Implied context regarding the urgency of patent expiry)
• "I'm not really sure they overpaid... this was kind of like in the 4 to 5 times range, which seems pretty practical and really in line with a lot of the recent deals." (Jared on Merck's acquisition of Verona Pharma)
• "I do think there's a lot of urgency out there." (Jared on the broader M&A landscape)
• "They're clearly, you know, using this string of pearls strategy to, you know, supplement Keytruda, which we all know is going to be a big issue for them in the latter part of the decade." (Jared on Merck's pipeline strategy)
• "So it's really across the board I think to your to your question, who needs assets? I think they all do." (Jared on the widespread need for acquisitions)
• "The only sector I've liked here, you know, to your point, has been biotech since the summer." (Jared on investment preferences)

Conclusion

The transcript emphasizes the critical juncture faced by major pharmaceutical companies due to impending patent expirations, particularly for blockbuster drugs like Keytruda. This has fueled an unprecedented surge in M&A activity, with companies like Merck strategically acquiring smaller biotechs (e.g., Verona Pharma) through a "string of pearls" approach to bolster their future pipelines. While the broader healthcare sector remains fraught with risks, the biotech segment has emerged as a highly attractive investment area due to this robust deal-making environment. Investors are advised to focus on small and mid-cap biotech companies as potential acquisition targets.